Dante Labs

  • Develops next-generation sequencing (NGS)-based whole-exome sequencing services, including diagnostic services, a machine learning-based analytics platform, and clinical advisory services
  • Its core differentiation is based on its Immensa software, which generates individualized reports for drug ...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

SOPHiA Genetics

Company Snapshot | July 19, 2021

The company was started by CEO Jurgi Camblong, Lars Steinmetz, and Pierre Hutter in 2011; it has raised $250 million in total funding, with $110 million from a Series F round in 2020. The company is a developer of SOPHiA DDM (Data‑Driven Medicine), an AI‑enabled SaaS platform that analyzes genomic, ... To read more, click here.


Company Snapshot | August 04, 2021

The company was started by CEO Alexander Bisignano and Santiago Munne in 2016; it has raised $18 million in funding to date, including $8 million from its most recent round in 2020. The company develops GeneCompass, a consumer genetic testing kit for preventative and holistic care, based on next‑... To read more, click here.

NovogeneAIT Genomics

Company Profile | April 29, 2022

NGS vendor providing high‑throughput genome sequencing services in a College of American Pathologists (CAP)‑certified laboratory and liquid biopsy‑based cancer diagnostics Core differentiation lies in having access to a strong IP portfolio in NGS processes and analyses and providing services in... Not part of subscription